Drug Discrimination Test
Objective: Evaluation of substance abuse-related side effects by assessing whether rats discriminate GLYX-13 from other drugs
This is a Drug Discrimination Test protocol using rat as the model organism. The procedure involves 3 procedural steps, 1 equipment items. Extracted from a 2012 paper published in Neuropsychopharmacology.
Model and subjects
rat • Not specified • unknown • Not specified • Not specified
Study window
Estimated timing pending
Core workflow
Drug discrimination test setup • Administration of test compounds • Behavioral observation and discrimination assessment
Primary readouts
- Discrimination of GLYX-13 from other drugs
- Presence or absence of substance abuse-related side effects
- Comparison of drug discrimination responses between GLYX-13 and ketamine
Key equipment and reagents
Verified items
0
Direct vendor links
0
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Drug discrimination test setup
Rats were tested in a drug discrimination paradigm to assess whether they could discriminate GLYX-13 from other drugs
Note: This test was used to evaluate substance abuse-related side effects
View evidence from paper
“antidepressant-like effects without exhibiting substance abuse-related, gating, and sedative side effects of ketamine in the drug discrimination”
Administration of test compounds
GLYX-13 and ketamine were administered to rats during the drug discrimination test
Note: Comparison between GLYX-13 and ketamine was made
View evidence from paper
“GLYX-13, a novel NMDAR glycine-site functional partial agonist, produces an antidepressant-like effect in the Porsolt, novelty induced hypophagia, and learned helplessness tests in rats without exhibiting substance abuse-related”
Behavioral observation and discrimination assessment
Rats were observed to determine if they discriminated GLYX-13 from other drugs based on behavioral responses
Note: Results were compared between GLYX-13 and ketamine to assess for substance abuse-related side effects
View evidence from paper
“drug discrimination, conditioned place preference, pre-pulse inhibition and open-field tests”